Bit.bio - About the company
Bit.bio is a series C company based in Cambridge (United Kingdom), founded in 2016 by Florian Schuster and Mark Kotter. It operates as a Manufacturer of programmed human cells for research and drug discovery. Bit.bio has raised $266M in funding from investors like M&G, Arch Venture Partners and Tencent, with a current valuation of $*****. The company has 113 active competitors, including 30 funded and 15 that have exited. Its top competitors include companies like CytoTronics, Kiyatec and Saguaro.
Company Details
Manufacturer of programmed human cells for research and drug discovery. This entity utilizes gene-targeting technology to express transcription factors that reprogram induced pluripotent stem cells into defined human cell types. These products include various nerve, immune, and muscle cell lines designed for use in laboratory assays, disease modeling, and therapeutic development. The technology enables the production of consistent cell models for applications such as CRISPR screening, electrophysiology, and immunocytochemistry.
- Website
- www.bit.bio/
- Social
- Email ID
- *****@bit.bio
- Phone Number
- +44 **********
- Registered Address
- Pioneer House Vision Park, Histon, Cambridge, Cambridgeshire, United Kingdom, CB24 9NL
Key Metrics
Founded Year
2016
Location
Cambridge, United Kingdom
Stage
Series C
Total Funding
$266M in 7 rounds
Latest Funding Round
Post Money Valuation
$***** as on Dec 31, 2021
Ranked
1st among 113 active competitors
Annual Revenue
£6.91M as on Dec 31, 2024
Employee Count
163 as on Mar 31, 2026
Similar Companies
Legal entities associated with Bit.bio
Bit.bio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Bit Bio Ltd CIN: 10466798 , United Kingdom, Active | Nov 06, 2016 | $8.83M (As on Dec 31, 2024) | 219 (As on Dec 31, 2024) |
Sign up to download Bit.bio's company profile
Bit.bio's funding and investors
Bit.bio has raised a total funding of $266M over 7 rounds. Its first funding round was on Sep 15, 2017. Its latest funding round was a Series C round on Jan 09, 2026 for $*****. 1 investor participated in its latest round. Bit.bio has 36 institutional investors and 19 angel investors.
Here is the list of recent funding rounds of Bit.bio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 09, 2026 | 9406175 | Series C | 8827873 | 2000255 | 4204752 | 3751857 |
Dec 16, 2024 | 1051840 | Series B | 5046576 | 2944125 | 6846710 | |
Dec 31, 2021 | 9820601 | Series B | 3628939 | 3330398 | 1431943 | 6256057 |
Access funding benchmarks and valuations. Sign up today!View details of Bit.bio's funding rounds and investors
Bit.bio's founders and board of directors
Founder? Claim ProfileThe founders of Bit.bio are Florian Schuster and Mark Kotter.
Here are the details of Bit.bio's key team members:
- Florian Schuster: Former Co-Founder of Bit.bio. They are also an angel investor in 1 startup and serve on the board of 1 company.
- Mark Kotter: Co-Founder of Bit.bio and founder of 2 other companies, Elpis BioMed and Elpis Biomed. They serve on the board of 1 company.Contact Info: 2 email addresses
Bit.bio's Board of Directors
Bit.bio's board has 6 active members. Mark Kotter and Przemek Obloj are part of team and David Prior, Corneliu Chiriac, Keying Xi and Klevin Lo are independent board members.Here is the list of Bit.bio's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 9y 5m | |
Team | - | Current | 1y 2m | |
Independent board member | - | Current | 0y 3m | |
rrfpnzf | Independent board member | - | Current | 5y 8m |
cgipkyi | Independent board member | - | Current | 2y 7m |
bqgsnrw | Independent board member | - | Current | 3y 7m |
View details of Bit.bio's Founder profiles and Board Members
Bit.bio's employee count trend
Bit.bio has 163 employees as of Mar 26. Here is Bit.bio's employee count trend over the years:
Uncover Bit.bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Bit.bio's Competitors and alternates
Top competitors of Bit.bio include CytoTronics, Kiyatec and Saguaro. Here is the list of Top 10 competitors of Bit.bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Bit.bio 2016, Cambridge (United Kingdom), Series C | Manufacturer of programmed human cells for research and drug discovery | $266M | 68/100 | |
2nd |  CytoTronics 2015, Boston (United States), Series A | Developer of cell-based assays for drug discovery | $22.7M | 57/100 | |
3rd | Kiyatec 2005, Pendleton (United States), Series C | Develops 3D phenotypic cell-based assays and diagnostic solutions for prediction of patients’ response to cancer drug treatment | $29.5M | 55/100 | |
4th | Developer of 3D cell culture products for drug discovery | $4.1M | 47/100 | ||
5th | Developer of in-vitro diagnostic products for the detection of cancer | $8.05M | 47/100 | ||
6th |  Cytotheryx 2018, Rochester (United States), Series A | Developer of human hepatocytes for research and clinical applications | $60M | 47/100 | |
7th |  Nanocrine 2018, Frederick (United States), Seed | Provider of a cell analysis and drug design tool for researchers | $300K | 43/100 | |
8th | StemBioSys 2010, San Antonio (United States), Series A | Cell culture technology company advancing regenerative medicine and drug discovery | $14.5M | 41/100 | |
9th | Supplier of ion channel, GPCR and neural signaling tools | - | - | 41/100 | |
10th | SK Plasma 1970, Seongnam-si (South Korea), Funding Raised | Manufactures plasma derivatives | - | 41/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Bit.bio's competitors? Click here to see the top ones
Bit.bio's Investments and acquisitions
Bit.bio has made no investments or acquisitions yet.
News related to Bit.bio
Filter this listMedia has covered Bit.bio for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
bit.bio Accelerates Global Access to Human Cells with New Pricing Model and Distribution HubBusiness Wire•Feb 19, 2026•bit.bio
•
Bit.bio Secures $50M Series C to Advance Human Cell ProgrammingStartup Rise EU•Jan 12, 2026•bit.bio, M&G
•
People Cell/Gene Tx Stem cell company bit.bio cuts quarter of staff, drops therapeutics focusEndPoints News•Mar 19, 2025•bit.bio
•
•
bit.bio Raises $30 Million Led by M&G Investments to Focus on Tools for the Research, Drug Discovery and Cell Therapy MarketsPR Newswire•Dec 16, 2024•bit.bio, M&G, Arch Venture Partners, BlueYard and 3 others
•
bit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming TechnologyBusiness Wire•Oct 16, 2024•bit.bio
•
bit.bio defends European patent for ‘novel’ opti-ox technologyPharmaceutical Technology•Oct 16, 2024•bit.bio
•
bit.bio Expands Executive Team with Appointment of Przemek Obloj as Chief Financial OfficerBusiness Wire•Jul 31, 2024•bit.bio
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Bit.bio
Explore our recently published companies
- Hygee - Unfunded company
- Ducon - 2007 founded, Unfunded company
- Objektdesign-Georgdietrich - Unfunded company
- Gaobras - Unfunded company
- Innovis - 2017 founded, Unfunded company
- Projectintegration - 1993 founded, Unfunded company
